SEARCH

SEARCH BY CITATION

References

  • Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B. & Crowley, J. (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93, 5565.
  • Bataille, R., Magub, M., Grenier, J., Donnadio, O. & Sany, J. (1982) Serum β2 microglobulin in multiple myeloma: relation to presenting features and clinical status. European Journal of Cancer and Clinical Oncology, 18, 5966.
  • Bataille, R., Durie, B.G.M., Grenier, J. & Sany, J. (1986) Prognostic factors and staging in multiple myeloma: a reappraisal. Journal of Clinical Oncology, 4, 8087.
  • Bataille, R., Jourdan, M., Zhang, X.G. & Klein, B. (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation, 84, 20082011.
  • Berenson, R., Crowley, J.J., Grogan, T.M., Zangari, M., Briggs, A.D., Mills, G.M., Barlogie, B. & Salmon, S.E. (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood, 99, 31633168.
  • Berggarrd, I. & Beam, A.G. (1968) Isolation and properties of a low molecular weight β2 microglobulin occurring in human biological fluids. Biology Chemistry, 243, 40955002.
  • Cassuto, J.P., Krebs, B.P., Viot, G., Dujardin, P. & Masseyefl, R. (1978) β2 microglobulin: a tumour marker of lymphoproliferative disorders. Lancet, 2, 950.
  • Child, J.A., Crawford, S.M., Norfolk, D.R., O'Quigley, J., Scarffe, J.H. & Struthers, L.P.L. (1983) Evaluation of serum β2-microglobulin as a prognostic indicator in myelomatosis. British Journal of Cancer, 47, 111114.
  • Cox, D.R. (1972) Regression models and life-tables (with discussion). Journal of the Royal Statistical Society, Series B, 34, 187220.
  • Crowley, J.J., LeBlanc, M., Jacobson, J.L. & Salmon, S.E. (1997) Some exploratory tools for survival analysis. Lecture notes in statistics. Proceedings of the First Seattle Symposium in Biostatistics, 199229.
  • Dimopoulos, M.A., Zervas, K., Pouli, A., Hamilos, G., Mitsouli, C., Repousis, P., Symeonidis, A., Gika, D., Stamatelou, M., Anagnostopoulos, N. & Maniatis, A. for the Greek Myeloma Study Group (GMSG) (2002) Independent validation of the Southwest Oncology Group (SWOG) staging system: a clinically useful staging system for multiple myeloma. Blood, 100, 2361.
  • Durie, B.G.M. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Cancer, 36, 842854.
  • Durie, B.G.M., Stock-Novack, D., Salmon, S.E., Finley, P., Beckford, J., Crowley, J. & Coltman, C.A. (1990) Prognostic value of pretreatment serum B2 microglobulin in myeloma: a Southwest Oncology Group study. Blood, 75, 823830.
  • Ershler, W.B. & Keller, E.T. (2000) Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annual Review of Medicine, 51, 245270.
  • Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Genevieve, F., Zandecki, M., Laý, J., Leleu, X., Jouet, J.P., Bauters, F., Harousseau, J.L., Bataille, R. & Mary, J.Y. (2001) Chromosome 13 abnormalities identified by FISH analysis and serum b2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood, 97, 15661571.
  • Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation for incomplete observations. Journal of the American Statistical Association, 53, 457481.
  • Kin, K., Kasahara, T., Itoh, Y., Sakurabayashi, I., Kawai, T. & Morita, M. (1979) β2-microglobulin production by highly purified human T and B lymphocytes in cell culture stimulated with various mitogens. Immunology, 36, 4754.
  • LeBlanc, M. & Crowley, J.J. (1993) Survival trees by goodness of split. Journal of the American Statistical Association, 88, 457467.
  • Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports, 50, 163170.
  • Mazolewski, P., Turner, J.F., Baker, M., Kurtz, T. & Little, A.G. (1999) The impact of nutritional status on the outcome of lung volume reduction surgery: a prospective study. Chest, 116, 693696 .
  • Mori, M., Terui, Y., Ikeda, M., Tomizuka, H., Uwai, M., Kasahara, T., Kubota, N., Itoh, T., Mishima, Y., Douzono-Tanaka, M., Yamada, M., Shimamura, S., Kikuchi, J., Furukawa, Y., Ishizaka, Y., Ikeda, K., Mano, H., Ozawa, K. & Hatake, K. (1999) β2-microglobulin identified as an apoptosis-inducing factor and its characterization. Blood, 94, 27442753 .
  • Norfolk, D., Child, J.A., Cooper, E.H., Kerruish, G. & Ward, A.M. (1980) Serum β2 microglobulin in myelomatosis: potential value in stratification and monitoring. British Journal of Cancer, 42, 510.
  • Peest, D., Bartels, B., Dallmann, I., Schedel, I. & Deicher, H. (1986) Cytostatic drug sensitivity test for human multiple myeloma, measuring monoclonal immunoglobulin produced by bone marrow cells its vitro. Cancer Chemotherapy and Pharmacology, 17, 6974 .
  • Peterson, P.A., Cunningham, B.A., Berggárd, I. & Edelman, G.M. (1972) β2-microglobulin: a free immunoglobulin domain. Proceedings of the National Academy of Sciences of the United States of America, 69, 16971701.
  • Salmon, S.E., Tesh, D., Crowley, J.J., Saeed, S., Finley, P., Milder, M.S., Hutchins, L.F., Coltman, Jr, C.A., Bonnet, J.D., Cheson, B., Knost, J.A., Samhouri, A., Beckford, J. & Stock-Novack, D. (1990) Chemotherapy is superior to sequential hemibody radiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. Journal of Clinical Oncology, 8, 15751584.
  • Salmon, S.E., Crowley, J.J., Grogan, T.M., Finley, P., Pugh, R.P. & Barlogie, B. (1994) Combination chemotherapy, glococorticoids, and alpha interferon in the treatment of multiple myeloma: a Southwest Oncology Group study. Journal of Clinical Oncology, 12, 24052414.
  • Salmon, S.E., Crowley, J.J., Balcerzak, S.P., Roach, R.W., Taylor, S.A., Rivkin, S.E. & Samlowski, W. (1998) Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology, 16, 589592 .